Nestec S.a.

Societe Des Produits Nestle S.a.

Netsec S.a.

Serge Andre Dominique Rezzi

Francois-Pierre Martin

Philippe Alexandre Guy

Ivan Montoliu Roura

Sebastiano Collino

Steven Scott Hannah

Brian Michael Zanghi

Rondo Paul Middleton

Francia Jacqueline Arce Vera

Stephane Duboux

Sunil Kochhar

Bertrand Bourqui

Nicolas Page

Francis Foata

Timo Buetler

Jeremy Kirk Nicholson

Elaine Holmes

Marc-Emmanuel Dumas

Claire L Boulange

Steven S Hannah

Denis Breuille

Stephanie Blum-Sperisen

Magali Faure

Yuanlong Pan

Marjorie Guitard

Sylvain Lengacher

Pierre Julius Magistretti

Jane Durga

Rondo P Middleton

Ivan Montoliu Rora

Emma Peré-Trepat

Evelyne Ruchti

Igor Allaman

Brian M Zanghi

Emma Pere-Trepat

Francoise-Pierre Martin

Francia Arce Vera

A pet food composition contains protein, carbohydrates, fat, fiber, and at least 6 distinct metabolites. The at least 6 distinct metabolites include first and second metabolites for modulating bone mineral content, third and fourth metabolites for modulating 25(OH) vitamin D3, and fifth and sixth metabolites for modulating 1,25(OH)vitamin D3 in a companion animal.

Pet food compositions that modulate vitamin D and bone mineral content in a companion animal

A specific type of organ health marker in a companion animal can be improved by adjusting the diet of the animal to increase the amount of a compound which positively or negatively modulates the specific type of organ health marker or adjusting the diet of the animal to decrease the amount of a compound which positively or negatively modulates the specific type of organ health marker. The specific type of organ health marker can be one or more of phosphorus, alkaline phosphatase, aspartate aminotransferase, or gamma-glutamyltransferase.

Compositions and methods that modulate phosphorus or enzymes in a companion animal

Bone mineral content, 25(OH) vitamin D3, or 1,25(OH)vitamin D3 in a companion animal can be improved by adjusting the diet of the animal to increase the amount of a compound which positively or negatively modulates the bone mineral content, 25(OH) vitamin D3, or 1,25(OH)vitamin D3 or adjusting the diet of the animal to decrease the amount of a compound which positively or negatively modulates the bone mineral content, 25(OH) vitamin D3, or 1,25(OH)vitamin D3.

Compositions and methods that modulate vitamin D and bone mineral content in a companion animal

The present invention relates to a method for determining the distinctive nutritional requirements of a patient with specific nutritional needs and providing a composition meeting the distinctive nutritional requirements of said patient.

Method for determining the distinctive nutritional requirements of a patient

White blood cells and/or neutrophils in a companion animal can be improved by adjusting the diet of the animal to increase the amount of a compound which positively or negatively modulates the white blood cells and/or neutrophils or adjusting the diet of the animal to decrease the amount of a compound which positively or negatively modulates the white blood cells and/or neutrophils.

Compositions and methods that modulate white blood cells or neutrophils in a companion animal

Cholesterol, high-density lipoproteins, and low-density lipoproteins in a companion animal can be improved by adjusting the diet of the animal to increase the amount of a compound which positively or negatively modulates the cholesterol, high-density lipoproteins, or low-density lipoproteins or adjusting the diet of the animal to decrease the amount of a compound which positively or negatively modulates cholesterol, high-density lipoproteins, or low-density lipoproteins.

Compositions and methods that modulate cholesterol in a companion animal

A specific type of digestibility in a companion animal can be improved by adjusting the diet of the animal to increase the amount of a compound which positively or negatively modulates the specific type of digestibility or adjusting the diet of the animal to decrease the amount of a compound which positively or negatively modulates the specific type of digestibility. The specific type of digestibility can be one or more of organic matter digestibility, dry matter digestibility, fiber digestibility, energy digestibility, fat digestibility, or protein digestibility.

Compositions and methods that modulate digestibility in a companion animal

The present invention relates generally to the field of nutrition and health. In particular, the present invention relates to a new biomarker, its use and a method that allows it to diagnose the likelihood to resist diet induced weight gain, and/or to be susceptible to a diet induced weight gain. For example, the biomarker may be trimethylamine-N-oxide.

Trimethylamine-N-oxide as biomarker for the predisposition for weight gain and obesity

Using NMR/MS based metabonomics and targeted lipidomics approaches the inventors have explored the metabolic phenotypes of aging and longevity in a cohort including centenarians, elderly and young adults. The inventors have identified biomarkers for a reduced risk of developing ageing related chronic inflammatory disorders and propose a method of diagnosing a lifestyle that allows delaying and/or avoiding ageing related chronic inflammatory disorders using 9-oxo-ODE as biomarker.

9-oxo-HODE as a biomarker for healthy aging

The present invention relates generally to the field of enhancing skin appearance. One aspect of the invention aims to provide a composition comprising 4-oxo-2-pentenoic acid for use in the reduction or prevention of regions of the skin with darker pigmentation. The present invention also relates to cosmetic use of a composition comprising 4-oxo-2-pentenoic acid for the reduction or prevention of regions of the skin with darker pigmentation.

4-oxo-2-pentenoic acid and skin pigmentation

The present invention relates generally to the field of nutrition and health. In particular, the present invention relates to a new biomarker, its use and a method that allows it to diagnose the likelihood to resist diet induced weight gain, and/or to be susceptible to a diet induced weight gain. For example, the biomarker may be isovalerylglycine.

Isovalerylglycine as biomarker for the predispositon for weight gain and obesity

The present invention relates generally to compositions with a health benefit. In particular, the invention relates to treatment or prevention of liver disorders. A subject matter of the invention is a composition comprising 4-oxo-2-pentenoic acid for use in the treatment or prevention of liver disorders. A further subject matter of the invention is a composition comprising 4-oxo-2-pentenoic acid for use in the treatment or prevention of liver disorders linked to an insufficient activity of phase II enzymes in the liver.

4-oxo-2-pentenoic acid and liver disorders

The present invention relates generally to the field of nutrition and health. In particular, the present invention relates to a new biomarker, its use and a method that allows it to diagnose the likelihood to resist diet induced weight gain, and/or to be susceptible to a diet induced weight gain. For example, the biomarker may be hexanoylglycine.

Hexanoylglycine as biomarker for the predisposition for weight gain and obesity

Growing community of inventors

Semsales, Switzerland

Serge Andre Dominique Rezzi